Clinical Trial

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study acronym: CaDAnCe-101
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Protocol Amendment History 3 changes
notable Trial sites reduced: 127 -> 114 locations 2026-08-07
notable Trial sites reduced: 130 -> 127 locations 2026-06-19
notable Trial sites expanded: 120 -> 126 locations 2026-04-16
Trial Details
NCT Number NCT05006716
Lead Sponsor BeOne Medicines
Conditions B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma +1 more
Enrollment 645 participants
Start Date 2021-09-13
Primary Completion 2026-11 (estimated)
Study Completion 2029-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-06